The Effect of Photobiomodulation on Pressure Ulcers
Pressure Ulcer
2 other identifiers
interventional
46
0 countries
N/A
Brief Summary
Photobiomodulation Group (Intervention Group): Before the intervention, the patient's skin sensitivity to light will be tested by applying light for 3 minutes to one-fourth of the forearm skin. If redness occurs and persists for more than 2 hours, this indicates photosensitivity, and the intervention will not be performed. The Patient Information Form will be completed during the first meeting with the patients included in the study. Subsequently, blood values will be determined, the Patient Assessment Form will be filled out, vital signs will be measured, and then the intervention will begin. After routine wound care/cleaning procedures in the intensive care unit, without applying any medication, cream, or lotion to the wound area, red light (660 nm wavelength) will be applied to the wound area for 5 minutes at a distance of 55 cm during the first 3 days, and for 10 minutes at the same distance on the following days. This application will continue once daily for 14 days. Wound assessments will be performed, and photographs will be taken on Day 1, Day 4, Day 7, and Day 14 (Baracho et al., 2021; Viecelli et al., 2024; Lima et al., 2020). Control Group: The Patient Information Form will be completed during the first meeting with the patients included in the study. Subsequently, blood values will be determined, the Patient Assessment Form will be filled out, and vital signs will be measured. No intervention will be performed other than the routine wound care procedure carried out in the intensive care unit. Wound assessments will be performed, and photographs will be taken on Day 1, Day 4, Day 7, and Day 14, in the same manner as in the intervention group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 8, 2025
CompletedFirst Posted
Study publicly available on registry
December 29, 2025
CompletedStudy Start
First participant enrolled
May 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 20, 2027
March 9, 2026
March 1, 2026
11 months
December 8, 2025
March 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The healing of pressure sores in the patients in the experimental group will be faster and more effective than in the control group.
This application will be continued once a day for 14 days and wound evaluation will be made and wound photographs will be taken on days 1, 4, 7 and 14. Wound assessment will be based on Pressure Ulcer Scale for Healing-PUSH and wound measurement(diameter).
14 days
Study Arms (2)
photobiomodulation group
EXPERIMENTALphotobiomodulation intervention group
control group
NO INTERVENTIONroutine hospital care
Interventions
The effectiveness of photobiomodulation application in chronic wound healing will be evaluated.
Eligibility Criteria
You may qualify if:
- Patients with Stage II pressure ulcers
- Patients without any skin disease
- Patients with albumin, platelet, and blood glucose levels within normal ranges
- Patients who will stay in the intensive care unit for 14 days or longer
- Patients with a BMI of 35 or below
- Patients with vital signs within normal limits
- Patients with an oxygen saturation level of 90% or above
You may not qualify if:
- Patients who do not consent to participate in the study
- Patients with severe nutritional problems and those who are cachectic
- Patients with severe edema (+4 or above)
- Patients with diabetes mellitus
- Patients who show photosensitivity in the light sensitivity test
- Patients with metastatic tumors, high fever, thromboangiitis obliterans, vascular insufficiency, active tuberculosis, acute soft tissue infection, pregnancy, bleeding tendency, skin sensory disorders, or skin allergies
- Patients with acute injuries within the past 72 hours
- Patients with a pacemaker, defibrillator, or other electronic implants
- Patients taking medications known to cause photosensitivity
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fenerbahce Universitycollaborator
- Ankara Medipol Universitylead
- Dr. Lutfi Kirdar Kartal Training and Research Hospitalcollaborator
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Asst Prof
Study Record Dates
First Submitted
December 8, 2025
First Posted
December 29, 2025
Study Start
May 1, 2026
Primary Completion (Estimated)
March 20, 2027
Study Completion (Estimated)
May 20, 2027
Last Updated
March 9, 2026
Record last verified: 2026-03